Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：34

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[31] Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study
Miller, D. H.
Hutchinson, M.
Fox, R. J.
Phillips, J. T.
Kita, M.
Havrdova, E.
O'Gorman, J.
Yang, M.
Viglietta, V.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 189 - 190
[32] Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
Fox, Robert
Miller, David
Phillips, J. Theodore
Arnold, Douglas
Selmaj, Krzysztof
Yang, Minhua
Zhang, Ray
Dawson, Katherine
Viglietta, Vissia
Sheikh, Sarah
Gold, Ralf
NEUROLOGY, 2013, 80
[33] An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies
Bar-Or, A.
Fox, R. J.
Gold, R.
Miller, D. H.
Arnold, D. L.
O'Gorman, J.
Yang, M.
Sheikh, S. I.
Viglietta, V.
Dawson, K. T.
Hutchinson, M.
JOURNAL OF NEUROLOGY, 2013, 260 : S13 - S13
[34] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study
Amit Bar-Or
Ralf Gold
Ludwig Kappos
Douglas L. Arnold
Gavin Giovannoni
Krzysztof Selmaj
John O’Gorman
Monica Stephan
Katherine T. Dawson
Journal of Neurology, 2013, 260 : 2297 - 2305
[35] Efficacy of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis in patients from Europe: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
Hutchinson, M.
Fox, R. J.
Bar-Or, A.
Havrdova, E.
Yang, M.
Zhang, R.
Viglietta, V.
Sheikh, S. I.
Gold, R.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 466 - 466
[36] Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study
Fox, Robert
Miller, David
Phillips, J. Theodore
Kita, Mariko
Hutchinson, Michael
Havrdova, Eva
Yang, Minhua
Zhang, Ray
Viglietta, Vissia
Dawson, Katherine
NEUROLOGY, 2012, 78
[37] Safety and Tolerability of Oral BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): Interim Results from ENDORSE Extension Study
Phillips, J. Theodore
Fox, Robert
Selmaj, Krzysztof
Raghupathi, Kartik
Yuan, Huixing
Novas, Mark
Sweetser, Marianne
Viglietta, Vissia
Dawson, Katherine
Gold, Ralf
NEUROLOGY, 2013, 80
[38] CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES
Bar-Or, A.
Fox, R. J.
Gold, R.
Miller, D. H.
Arnold, D. L.
O'Gorman, J.
Yang, M.
Sheikh, S., I
Viglietta, V.
Dawson, K. T.
Hutchinson, M.
VALUE IN HEALTH, 2013, 16 (03) : A102 - A102
[39] Clinical and Neuroradiologic Efficacy of BG-12 (Dimethyl Fumarate) in US Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
Kita, Mariko
Fox, Robert
Phillips, J. Theodore
Arnold, Douglas
Bar-Or, Amit
Yang, Minhua
Zhang, Ray
Dawson, Katherine
Viglietta, Vissia
Sheikh, Sarah
Gold, Ralf
NEUROLOGY, 2013, 80
[40] Clinical Efficacy and Safety of Oral Bg-12 (Dimethyl Fumarate) In Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 Define and Confirm Studies
Bar-Or, A.
Gold, R.
Fox, R. J.
Havrdova, E.
Selmaj, K.
Kurukulasuriya, N. C.
Yang, M.
Raghupathi, K.
Novas, M.
Sweetser, M. T.
Viglietta, V.
Dawson, K. T.
Phillips, J. T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1828 - 1828

← 1 2 3 4 5 →